{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Shi J"],"funding":["Chinese Academy of Medical Science Clinical and Translational Medicine Research Foundation","National Natural Science Foundation of China","Emergency Key Program of Guangzhou Laboratory","Capital Health Development Scientific Research Project"],"pagination":["19"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9835228"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["21(1)"],"pubmed_abstract":["<h4>Background</h4>Due to the temporal and spatial heterogeneity of human epidermal growth factor receptor 2 (HER2) expression in breast tumors, immunohistochemistry (IHC) cannot accurately reflect the HER2 status in real time, which may cause misguided treatment decisions. HER2-specific imaging can noninvasively determine HER2 status in primary and metastatic tumors. In this study, HER2 expression in breast cancer patients was determined in vivo by SPECT/CT of <sup>99m</sup>Tc-HP-Ark2, comparing with PET/CT of <sup>18</sup>F-FDG lesion by lesion.<h4>Methods</h4>A novel HER2-targeted peptide probe <sup>99m</sup>Tc-HP-Ark2 was constructed. Biodistribution and nanoScan SPECT/CT imaging were performed in mice models. The correlation between the quantified tumor uptake and HER2 expression in t"],"journal":["Journal of translational medicine"],"pubmed_title":["Molecular imaging of HER2 expression in breast cancer patients using a novel peptide-based tracer <sup>99m</sup>Tc-HP-Ark2: a pilot study."],"pmcid":["PMC9835228"],"funding_grant_id":["2018-1-4011","81927802","81630045","92159201","EKPG21-16","81971676","2019XK320032"],"pubmed_authors":["Luo Q","Du S","Zhu Z","Wang R","Wang F","Gao H","Shi J","Zhou Y","Hou G"],"additional_accession":[]},"is_claimable":false,"name":"Molecular imaging of HER2 expression in breast cancer patients using a novel peptide-based tracer <sup>99m</sup>Tc-HP-Ark2: a pilot study.","description":"<h4>Background</h4>Due to the temporal and spatial heterogeneity of human epidermal growth factor receptor 2 (HER2) expression in breast tumors, immunohistochemistry (IHC) cannot accurately reflect the HER2 status in real time, which may cause misguided treatment decisions. HER2-specific imaging can noninvasively determine HER2 status in primary and metastatic tumors. In this study, HER2 expression in breast cancer patients was determined in vivo by SPECT/CT of <sup>99m</sup>Tc-HP-Ark2, comparing with PET/CT of <sup>18</sup>F-FDG lesion by lesion.<h4>Methods</h4>A novel HER2-targeted peptide probe <sup>99m</sup>Tc-HP-Ark2 was constructed. Biodistribution and nanoScan SPECT/CT imaging were performed in mice models. The correlation between the quantified tumor uptake and HER2 expression in t","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2026-05-28T06:11:43.086Z","creation":"2025-02-19T02:22:02.482Z"},"accession":"S-EPMC9835228","cross_references":{"pubmed":["36631812"],"doi":["10.1186/s12967-022-03865-y"]}}